Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Fulgent Genetics Inc is a diagnostics & research business based in the US. Fulgent Genetics shares (FLGT) are listed on the NASDAQ and all prices are listed in US Dollars. Fulgent Genetics employs 480 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $60.70 |
|---|---|
| 52-week range | $62.50 - $189.89 |
| 50-day moving average | $89.52 |
| 200-day moving average | $86.04 |
| Wall St. target price | $141.00 |
| PE ratio | 4.1961 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $19.06 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $60.7 from 2022-01-21
| 1 week (2022-01-14) | -24.09% |
|---|---|
| 1 month (2021-12-22) | -41.72% |
| 3 months (2021-10-22) | -27.79% |
| 6 months (2021-07-22) | -29.42% |
| 1 year (2021-01-22) | -12.33% |
|---|---|
| 2 years (2020-01-22) | 335.44% |
| 3 years (2019-01-22) | 1,476.62% |
| 5 years (2017-01-20) | 358.81% |
Valuing Fulgent Genetics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Fulgent Genetics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Fulgent Genetics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, Fulgent Genetics shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Fulgent Genetics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.32. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Fulgent Genetics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Fulgent Genetics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $767.7 million.
The EBITDA is a measure of a Fulgent Genetics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1 billion |
|---|---|
| Operating margin TTM | 73.28% |
| Gross profit TTM | $331.9 million |
| Return on assets TTM | 65.35% |
| Return on equity TTM | 92.39% |
| Profit margin | 54.96% |
| Book value | $34.76 |
| Market capitalisation | $2.4 billion |
TTM: trailing 12 months
We're not expecting Fulgent Genetics to pay a dividend over the next 12 months.
Over the last 12 months, Fulgent Genetics's shares have ranged in value from as little as $62.5 up to $189.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fulgent Genetics's is 1.3381. This would suggest that Fulgent Genetics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Fulgent Genetics, Inc. , together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities; and has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.